nodes	percent_of_prediction	percent_of_DWPC	metapath
Capecitabine—TYMS—prostate cancer	0.426	1	CbGaD
Capecitabine—CYP2C9—Bicalutamide—prostate cancer	0.0429	0.34	CbGbCtD
Capecitabine—CYP2C9—Nilutamide—prostate cancer	0.0429	0.34	CbGbCtD
Capecitabine—CYP2C9—Estrone—prostate cancer	0.0257	0.204	CbGbCtD
Capecitabine—CYP2C9—Estradiol—prostate cancer	0.0147	0.117	CbGbCtD
Capecitabine—DPYD—prostate gland—prostate cancer	0.00537	0.108	CbGeAlD
Capecitabine—CDA—prostate gland—prostate cancer	0.00517	0.104	CbGeAlD
Capecitabine—CYP2C9—urine—prostate cancer	0.00325	0.0652	CbGeAlD
Capecitabine—TYMP—prostate gland—prostate cancer	0.00311	0.0625	CbGeAlD
Capecitabine—DPYD—bone marrow—prostate cancer	0.00277	0.0556	CbGeAlD
Capecitabine—CES1—prostate gland—prostate cancer	0.00269	0.0539	CbGeAlD
Capecitabine—TYMS—prostate gland—prostate cancer	0.00267	0.0536	CbGeAlD
Capecitabine—CDA—bone marrow—prostate cancer	0.00266	0.0534	CbGeAlD
Capecitabine—TYMP—seminal vesicle—prostate cancer	0.00263	0.0528	CbGeAlD
Capecitabine—DPYD—testis—prostate cancer	0.00237	0.0475	CbGeAlD
Capecitabine—CDA—testis—prostate cancer	0.00228	0.0457	CbGeAlD
Capecitabine—TYMP—urethra—prostate cancer	0.00208	0.0418	CbGeAlD
Capecitabine—DPYD—lymph node—prostate cancer	0.00172	0.0344	CbGeAlD
Capecitabine—CDA—lymph node—prostate cancer	0.00165	0.0331	CbGeAlD
Capecitabine—TYMP—bone marrow—prostate cancer	0.0016	0.0322	CbGeAlD
Capecitabine—TYMS—Docetaxel—Cabazitaxel—prostate cancer	0.00146	0.349	CbGdCrCtD
Capecitabine—TYMS—bone marrow—prostate cancer	0.00138	0.0276	CbGeAlD
Capecitabine—TYMP—testis—prostate cancer	0.00137	0.0275	CbGeAlD
Capecitabine—CES1—testis—prostate cancer	0.00118	0.0238	CbGeAlD
Capecitabine—TYMS—testis—prostate cancer	0.00118	0.0236	CbGeAlD
Capecitabine—TYMS—Paclitaxel—Cabazitaxel—prostate cancer	0.00101	0.241	CbGdCrCtD
Capecitabine—TYMP—lymph node—prostate cancer	0.000994	0.0199	CbGeAlD
Capecitabine—CES1—lymph node—prostate cancer	0.000858	0.0172	CbGeAlD
Capecitabine—TYMS—lymph node—prostate cancer	0.000853	0.0171	CbGeAlD
Capecitabine—TYMS—Paclitaxel—Docetaxel—prostate cancer	0.000418	0.1	CbGdCrCtD
Capecitabine—TYMS—Podofilox—Etoposide—prostate cancer	0.000269	0.0642	CbGdCrCtD
Capecitabine—TYMS—Levorphanol—Estrone—prostate cancer	0.000266	0.0636	CbGdCrCtD
Capecitabine—TYMS—Levorphanol—Estradiol—prostate cancer	0.000202	0.0482	CbGdCrCtD
Capecitabine—TYMS—Danazol—Ethinyl Estradiol—prostate cancer	0.000133	0.0318	CbGdCrCtD
Capecitabine—TYMS—Levonorgestrel—Ethinyl Estradiol—prostate cancer	9.55e-05	0.0228	CbGdCrCtD
Capecitabine—TYMS—Clobetasol propionate—Prednisone—prostate cancer	6.19e-05	0.0148	CbGdCrCtD
Capecitabine—TYMS—Flunisolide—Prednisone—prostate cancer	6.11e-05	0.0146	CbGdCrCtD
Capecitabine—TYMS—Triamcinolone—Prednisone—prostate cancer	6.05e-05	0.0144	CbGdCrCtD
Capecitabine—TYMS—Diflorasone—Prednisone—prostate cancer	5.57e-05	0.0133	CbGdCrCtD
Capecitabine—TYMS—Budesonide—Prednisone—prostate cancer	4.88e-05	0.0117	CbGdCrCtD
Capecitabine—TYMS—Danazol—Prednisone—prostate cancer	4.68e-05	0.0112	CbGdCrCtD
Capecitabine—Conjunctivitis—Doxorubicin—prostate cancer	2.65e-05	9.77e-05	CcSEcCtD
Capecitabine—Vertigo—Prednisone—prostate cancer	2.64e-05	9.75e-05	CcSEcCtD
Capecitabine—Haemorrhage—Epirubicin—prostate cancer	2.64e-05	9.75e-05	CcSEcCtD
Capecitabine—Hepatitis—Epirubicin—prostate cancer	2.64e-05	9.75e-05	CcSEcCtD
Capecitabine—Syncope—Prednisone—prostate cancer	2.64e-05	9.73e-05	CcSEcCtD
Capecitabine—Hypoaesthesia—Epirubicin—prostate cancer	2.63e-05	9.7e-05	CcSEcCtD
Capecitabine—Pharyngitis—Epirubicin—prostate cancer	2.63e-05	9.68e-05	CcSEcCtD
Capecitabine—Urinary tract disorder—Epirubicin—prostate cancer	2.61e-05	9.63e-05	CcSEcCtD
Capecitabine—Oedema peripheral—Epirubicin—prostate cancer	2.61e-05	9.6e-05	CcSEcCtD
Capecitabine—Hypotension—Docetaxel—prostate cancer	2.6e-05	9.59e-05	CcSEcCtD
Capecitabine—Haematuria—Doxorubicin—prostate cancer	2.6e-05	9.58e-05	CcSEcCtD
Capecitabine—Connective tissue disorder—Epirubicin—prostate cancer	2.6e-05	9.58e-05	CcSEcCtD
Capecitabine—Urethral disorder—Epirubicin—prostate cancer	2.59e-05	9.56e-05	CcSEcCtD
Capecitabine—Loss of consciousness—Prednisone—prostate cancer	2.59e-05	9.54e-05	CcSEcCtD
Capecitabine—Hepatobiliary disease—Doxorubicin—prostate cancer	2.58e-05	9.5e-05	CcSEcCtD
Capecitabine—Epistaxis—Doxorubicin—prostate cancer	2.57e-05	9.48e-05	CcSEcCtD
Capecitabine—Nausea—Estradiol—prostate cancer	2.57e-05	9.47e-05	CcSEcCtD
Capecitabine—Vomiting—Mitoxantrone—prostate cancer	2.56e-05	9.44e-05	CcSEcCtD
Capecitabine—Visual impairment—Epirubicin—prostate cancer	2.55e-05	9.39e-05	CcSEcCtD
Capecitabine—Agranulocytosis—Doxorubicin—prostate cancer	2.54e-05	9.38e-05	CcSEcCtD
Capecitabine—Hypertension—Prednisone—prostate cancer	2.54e-05	9.37e-05	CcSEcCtD
Capecitabine—Rash—Mitoxantrone—prostate cancer	2.54e-05	9.37e-05	CcSEcCtD
Capecitabine—Dermatitis—Mitoxantrone—prostate cancer	2.54e-05	9.36e-05	CcSEcCtD
Capecitabine—Musculoskeletal discomfort—Docetaxel—prostate cancer	2.54e-05	9.36e-05	CcSEcCtD
Capecitabine—Headache—Mitoxantrone—prostate cancer	2.52e-05	9.31e-05	CcSEcCtD
Capecitabine—Insomnia—Docetaxel—prostate cancer	2.52e-05	9.29e-05	CcSEcCtD
Capecitabine—Arthralgia—Prednisone—prostate cancer	2.51e-05	9.24e-05	CcSEcCtD
Capecitabine—Myalgia—Prednisone—prostate cancer	2.51e-05	9.24e-05	CcSEcCtD
Capecitabine—Paraesthesia—Docetaxel—prostate cancer	2.5e-05	9.22e-05	CcSEcCtD
Capecitabine—Erythema multiforme—Epirubicin—prostate cancer	2.5e-05	9.22e-05	CcSEcCtD
Capecitabine—Anxiety—Prednisone—prostate cancer	2.5e-05	9.21e-05	CcSEcCtD
Capecitabine—Bradycardia—Doxorubicin—prostate cancer	2.49e-05	9.18e-05	CcSEcCtD
Capecitabine—Unspecified disorder of skin and subcutaneous tissue—Prednisone—prostate cancer	2.49e-05	9.17e-05	CcSEcCtD
Capecitabine—CYP2C9—Biological oxidations—RXRA—prostate cancer	2.49e-05	0.000203	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism of lipids and lipoproteins—TNFRSF21—prostate cancer	2.49e-05	0.000203	CbGpPWpGaD
Capecitabine—Dyspnoea—Docetaxel—prostate cancer	2.48e-05	9.15e-05	CcSEcCtD
Capecitabine—Discomfort—Prednisone—prostate cancer	2.48e-05	9.13e-05	CcSEcCtD
Capecitabine—TYMS—Metabolism—P4HB—prostate cancer	2.48e-05	0.000202	CbGpPWpGaD
Capecitabine—Eye disorder—Epirubicin—prostate cancer	2.47e-05	9.11e-05	CcSEcCtD
Capecitabine—Hypersensitivity—Etoposide—prostate cancer	2.47e-05	9.1e-05	CcSEcCtD
Capecitabine—Tinnitus—Epirubicin—prostate cancer	2.47e-05	9.09e-05	CcSEcCtD
Capecitabine—Haemoglobin—Doxorubicin—prostate cancer	2.46e-05	9.07e-05	CcSEcCtD
Capecitabine—DPYD—Metabolism—CREBBP—prostate cancer	2.46e-05	0.0002	CbGpPWpGaD
Capecitabine—Flushing—Epirubicin—prostate cancer	2.45e-05	9.05e-05	CcSEcCtD
Capecitabine—Cardiac disorder—Epirubicin—prostate cancer	2.45e-05	9.05e-05	CcSEcCtD
Capecitabine—Rhinitis—Doxorubicin—prostate cancer	2.45e-05	9.04e-05	CcSEcCtD
Capecitabine—Dyspepsia—Docetaxel—prostate cancer	2.45e-05	9.04e-05	CcSEcCtD
Capecitabine—Hepatitis—Doxorubicin—prostate cancer	2.45e-05	9.02e-05	CcSEcCtD
Capecitabine—Haemorrhage—Doxorubicin—prostate cancer	2.45e-05	9.02e-05	CcSEcCtD
Capecitabine—Hypoaesthesia—Doxorubicin—prostate cancer	2.43e-05	8.97e-05	CcSEcCtD
Capecitabine—Pharyngitis—Doxorubicin—prostate cancer	2.43e-05	8.95e-05	CcSEcCtD
Capecitabine—TYMS—Integrated Pancreatic Cancer Pathway—PIK3CA—prostate cancer	2.43e-05	0.000198	CbGpPWpGaD
Capecitabine—Decreased appetite—Docetaxel—prostate cancer	2.42e-05	8.93e-05	CcSEcCtD
Capecitabine—CYP2C9—Metabolism of lipids and lipoproteins—CYP7B1—prostate cancer	2.42e-05	0.000197	CbGpPWpGaD
Capecitabine—Urinary tract disorder—Doxorubicin—prostate cancer	2.42e-05	8.91e-05	CcSEcCtD
Capecitabine—Oedema peripheral—Doxorubicin—prostate cancer	2.41e-05	8.89e-05	CcSEcCtD
Capecitabine—TYMP—Metabolism—CYP1A1—prostate cancer	2.41e-05	0.000196	CbGpPWpGaD
Capecitabine—TYMS—Metabolism—SLC22A1—prostate cancer	2.41e-05	0.000196	CbGpPWpGaD
Capecitabine—Gastrointestinal disorder—Docetaxel—prostate cancer	2.41e-05	8.86e-05	CcSEcCtD
Capecitabine—Asthenia—Etoposide—prostate cancer	2.41e-05	8.86e-05	CcSEcCtD
Capecitabine—Connective tissue disorder—Doxorubicin—prostate cancer	2.4e-05	8.86e-05	CcSEcCtD
Capecitabine—Oedema—Prednisone—prostate cancer	2.4e-05	8.86e-05	CcSEcCtD
Capecitabine—Fatigue—Docetaxel—prostate cancer	2.4e-05	8.85e-05	CcSEcCtD
Capecitabine—Angiopathy—Epirubicin—prostate cancer	2.4e-05	8.84e-05	CcSEcCtD
Capecitabine—Urethral disorder—Doxorubicin—prostate cancer	2.4e-05	8.84e-05	CcSEcCtD
Capecitabine—TYMS—Cell Cycle—ATM—prostate cancer	2.4e-05	0.000195	CbGpPWpGaD
Capecitabine—CYP2C9—Biological oxidations—COMT—prostate cancer	2.4e-05	0.000195	CbGpPWpGaD
Capecitabine—Nausea—Mitoxantrone—prostate cancer	2.39e-05	8.82e-05	CcSEcCtD
Capecitabine—TYMP—Metabolism—ERCC2—prostate cancer	2.39e-05	0.000195	CbGpPWpGaD
Capecitabine—Immune system disorder—Epirubicin—prostate cancer	2.39e-05	8.81e-05	CcSEcCtD
Capecitabine—Infection—Prednisone—prostate cancer	2.39e-05	8.8e-05	CcSEcCtD
Capecitabine—CYP2C9—Biological oxidations—GSTP1—prostate cancer	2.39e-05	0.000194	CbGpPWpGaD
Capecitabine—Mediastinal disorder—Epirubicin—prostate cancer	2.38e-05	8.79e-05	CcSEcCtD
Capecitabine—Constipation—Docetaxel—prostate cancer	2.38e-05	8.78e-05	CcSEcCtD
Capecitabine—Pain—Docetaxel—prostate cancer	2.38e-05	8.78e-05	CcSEcCtD
Capecitabine—Chills—Epirubicin—prostate cancer	2.37e-05	8.75e-05	CcSEcCtD
Capecitabine—Pruritus—Etoposide—prostate cancer	2.37e-05	8.74e-05	CcSEcCtD
Capecitabine—CYP2C9—Metapathway biotransformation—COMT—prostate cancer	2.36e-05	0.000193	CbGpPWpGaD
Capecitabine—Shock—Prednisone—prostate cancer	2.36e-05	8.71e-05	CcSEcCtD
Capecitabine—Arrhythmia—Epirubicin—prostate cancer	2.36e-05	8.71e-05	CcSEcCtD
Capecitabine—CDA—Metabolism—PIK3CG—prostate cancer	2.36e-05	0.000192	CbGpPWpGaD
Capecitabine—Visual impairment—Doxorubicin—prostate cancer	2.36e-05	8.69e-05	CcSEcCtD
Capecitabine—CYP2C9—Metabolism of lipids and lipoproteins—SRD5A1—prostate cancer	2.36e-05	0.000192	CbGpPWpGaD
Capecitabine—Nervous system disorder—Prednisone—prostate cancer	2.36e-05	8.68e-05	CcSEcCtD
Capecitabine—CYP2C9—Metapathway biotransformation—GSTP1—prostate cancer	2.35e-05	0.000192	CbGpPWpGaD
Capecitabine—TYMS—Metabolism—SULT2A1—prostate cancer	2.35e-05	0.000191	CbGpPWpGaD
Capecitabine—TYMS—Integrated Pancreatic Cancer Pathway—TP53—prostate cancer	2.35e-05	0.000191	CbGpPWpGaD
Capecitabine—Tachycardia—Prednisone—prostate cancer	2.34e-05	8.64e-05	CcSEcCtD
Capecitabine—Alopecia—Epirubicin—prostate cancer	2.34e-05	8.61e-05	CcSEcCtD
Capecitabine—Skin disorder—Prednisone—prostate cancer	2.33e-05	8.6e-05	CcSEcCtD
Capecitabine—DPYD—Metabolism—PIK3CD—prostate cancer	2.33e-05	0.00019	CbGpPWpGaD
Capecitabine—Hyperhidrosis—Prednisone—prostate cancer	2.32e-05	8.56e-05	CcSEcCtD
Capecitabine—Mental disorder—Epirubicin—prostate cancer	2.32e-05	8.54e-05	CcSEcCtD
Capecitabine—Erythema multiforme—Doxorubicin—prostate cancer	2.31e-05	8.53e-05	CcSEcCtD
Capecitabine—TYMS—Metabolism—MED12—prostate cancer	2.31e-05	0.000188	CbGpPWpGaD
Capecitabine—Malnutrition—Epirubicin—prostate cancer	2.3e-05	8.49e-05	CcSEcCtD
Capecitabine—Erythema—Epirubicin—prostate cancer	2.3e-05	8.49e-05	CcSEcCtD
Capecitabine—Feeling abnormal—Docetaxel—prostate cancer	2.3e-05	8.46e-05	CcSEcCtD
Capecitabine—Diarrhoea—Etoposide—prostate cancer	2.29e-05	8.45e-05	CcSEcCtD
Capecitabine—TYMS—Metabolism—GNG5—prostate cancer	2.29e-05	0.000187	CbGpPWpGaD
Capecitabine—Anorexia—Prednisone—prostate cancer	2.29e-05	8.44e-05	CcSEcCtD
Capecitabine—Eye disorder—Doxorubicin—prostate cancer	2.29e-05	8.43e-05	CcSEcCtD
Capecitabine—Tinnitus—Doxorubicin—prostate cancer	2.28e-05	8.41e-05	CcSEcCtD
Capecitabine—Gastrointestinal pain—Docetaxel—prostate cancer	2.28e-05	8.4e-05	CcSEcCtD
Capecitabine—Flushing—Doxorubicin—prostate cancer	2.27e-05	8.37e-05	CcSEcCtD
Capecitabine—Cardiac disorder—Doxorubicin—prostate cancer	2.27e-05	8.37e-05	CcSEcCtD
Capecitabine—Flatulence—Epirubicin—prostate cancer	2.27e-05	8.36e-05	CcSEcCtD
Capecitabine—Dysgeusia—Epirubicin—prostate cancer	2.25e-05	8.31e-05	CcSEcCtD
Capecitabine—TYMS—Circadian rythm related genes—TP53—prostate cancer	2.25e-05	0.000184	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism of lipids and lipoproteins—ACSL4—prostate cancer	2.25e-05	0.000183	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism of lipids and lipoproteins—HSD17B3—prostate cancer	2.25e-05	0.000183	CbGpPWpGaD
Capecitabine—TYMP—Metabolism—MTHFR—prostate cancer	2.25e-05	0.000183	CbGpPWpGaD
Capecitabine—CDA—Metabolism—INS—prostate cancer	2.24e-05	0.000182	CbGpPWpGaD
Capecitabine—Back pain—Epirubicin—prostate cancer	2.23e-05	8.21e-05	CcSEcCtD
Capecitabine—Angiopathy—Doxorubicin—prostate cancer	2.22e-05	8.18e-05	CcSEcCtD
Capecitabine—Dizziness—Etoposide—prostate cancer	2.22e-05	8.17e-05	CcSEcCtD
Capecitabine—Muscle spasms—Epirubicin—prostate cancer	2.21e-05	8.16e-05	CcSEcCtD
Capecitabine—Immune system disorder—Doxorubicin—prostate cancer	2.21e-05	8.15e-05	CcSEcCtD
Capecitabine—TYMS—Metabolism—NCOA3—prostate cancer	2.21e-05	0.00018	CbGpPWpGaD
Capecitabine—Mediastinal disorder—Doxorubicin—prostate cancer	2.21e-05	8.13e-05	CcSEcCtD
Capecitabine—TYMP—Metabolism—PPARA—prostate cancer	2.2e-05	0.00018	CbGpPWpGaD
Capecitabine—Body temperature increased—Docetaxel—prostate cancer	2.2e-05	8.12e-05	CcSEcCtD
Capecitabine—Abdominal pain—Docetaxel—prostate cancer	2.2e-05	8.12e-05	CcSEcCtD
Capecitabine—DPYD—Metabolism—NOS3—prostate cancer	2.2e-05	0.000179	CbGpPWpGaD
Capecitabine—Chills—Doxorubicin—prostate cancer	2.2e-05	8.09e-05	CcSEcCtD
Capecitabine—CYP2C9—Biological oxidations—GSTM1—prostate cancer	2.19e-05	0.000179	CbGpPWpGaD
Capecitabine—CDA—Metabolism—CREBBP—prostate cancer	2.19e-05	0.000178	CbGpPWpGaD
Capecitabine—Musculoskeletal discomfort—Prednisone—prostate cancer	2.19e-05	8.07e-05	CcSEcCtD
Capecitabine—Arrhythmia—Doxorubicin—prostate cancer	2.19e-05	8.06e-05	CcSEcCtD
Capecitabine—Insomnia—Prednisone—prostate cancer	2.17e-05	8.01e-05	CcSEcCtD
Capecitabine—Vision blurred—Epirubicin—prostate cancer	2.17e-05	8e-05	CcSEcCtD
Capecitabine—Alopecia—Doxorubicin—prostate cancer	2.16e-05	7.97e-05	CcSEcCtD
Capecitabine—CYP2C9—Metapathway biotransformation—GSTM1—prostate cancer	2.16e-05	0.000176	CbGpPWpGaD
Capecitabine—Paraesthesia—Prednisone—prostate cancer	2.16e-05	7.95e-05	CcSEcCtD
Capecitabine—Mental disorder—Doxorubicin—prostate cancer	2.14e-05	7.9e-05	CcSEcCtD
Capecitabine—Ill-defined disorder—Epirubicin—prostate cancer	2.14e-05	7.87e-05	CcSEcCtD
Capecitabine—Vomiting—Etoposide—prostate cancer	2.13e-05	7.86e-05	CcSEcCtD
Capecitabine—Erythema—Doxorubicin—prostate cancer	2.13e-05	7.85e-05	CcSEcCtD
Capecitabine—Malnutrition—Doxorubicin—prostate cancer	2.13e-05	7.85e-05	CcSEcCtD
Capecitabine—Anaemia—Epirubicin—prostate cancer	2.13e-05	7.84e-05	CcSEcCtD
Capecitabine—Dyspepsia—Prednisone—prostate cancer	2.11e-05	7.8e-05	CcSEcCtD
Capecitabine—Rash—Etoposide—prostate cancer	2.11e-05	7.79e-05	CcSEcCtD
Capecitabine—Dermatitis—Etoposide—prostate cancer	2.11e-05	7.78e-05	CcSEcCtD
Capecitabine—TYMS—Metabolism—HPGDS—prostate cancer	2.11e-05	0.000172	CbGpPWpGaD
Capecitabine—Headache—Etoposide—prostate cancer	2.1e-05	7.74e-05	CcSEcCtD
Capecitabine—Flatulence—Doxorubicin—prostate cancer	2.1e-05	7.74e-05	CcSEcCtD
Capecitabine—TYMS—Metabolism—CYP2C19—prostate cancer	2.09e-05	0.00017	CbGpPWpGaD
Capecitabine—Decreased appetite—Prednisone—prostate cancer	2.09e-05	7.7e-05	CcSEcCtD
Capecitabine—Dysgeusia—Doxorubicin—prostate cancer	2.09e-05	7.69e-05	CcSEcCtD
Capecitabine—CYP2C9—Biological oxidations—CYP1A1—prostate cancer	2.08e-05	0.000169	CbGpPWpGaD
Capecitabine—Malaise—Epirubicin—prostate cancer	2.08e-05	7.65e-05	CcSEcCtD
Capecitabine—CDA—Metabolism—PIK3CD—prostate cancer	2.08e-05	0.000169	CbGpPWpGaD
Capecitabine—TYMP—Metabolism—CAV1—prostate cancer	2.07e-05	0.000169	CbGpPWpGaD
Capecitabine—Fatigue—Prednisone—prostate cancer	2.07e-05	7.63e-05	CcSEcCtD
Capecitabine—Vertigo—Epirubicin—prostate cancer	2.07e-05	7.62e-05	CcSEcCtD
Capecitabine—Syncope—Epirubicin—prostate cancer	2.06e-05	7.61e-05	CcSEcCtD
Capecitabine—TYMS—Circadian rythm related genes—IL6—prostate cancer	2.06e-05	0.000168	CbGpPWpGaD
Capecitabine—Leukopenia—Epirubicin—prostate cancer	2.06e-05	7.6e-05	CcSEcCtD
Capecitabine—Back pain—Doxorubicin—prostate cancer	2.06e-05	7.6e-05	CcSEcCtD
Capecitabine—Constipation—Prednisone—prostate cancer	2.05e-05	7.57e-05	CcSEcCtD
Capecitabine—Hypersensitivity—Docetaxel—prostate cancer	2.05e-05	7.57e-05	CcSEcCtD
Capecitabine—CYP2C9—Metabolism—HAO1—prostate cancer	2.05e-05	0.000167	CbGpPWpGaD
Capecitabine—CYP2C9—Metapathway biotransformation—CYP1A1—prostate cancer	2.05e-05	0.000167	CbGpPWpGaD
Capecitabine—Muscle spasms—Doxorubicin—prostate cancer	2.05e-05	7.55e-05	CcSEcCtD
Capecitabine—TYMS—Metabolism—ACHE—prostate cancer	2.04e-05	0.000166	CbGpPWpGaD
Capecitabine—TYMS—Metabolism—GSTT1—prostate cancer	2.04e-05	0.000166	CbGpPWpGaD
Capecitabine—Palpitations—Epirubicin—prostate cancer	2.03e-05	7.5e-05	CcSEcCtD
Capecitabine—DPYD—Metabolism—PIK3CB—prostate cancer	2.03e-05	0.000165	CbGpPWpGaD
Capecitabine—Loss of consciousness—Epirubicin—prostate cancer	2.02e-05	7.46e-05	CcSEcCtD
Capecitabine—TYMS—Metabolism—CYP2A6—prostate cancer	2.02e-05	0.000164	CbGpPWpGaD
Capecitabine—DPYD—Metabolism—PTGS2—prostate cancer	2.01e-05	0.000164	CbGpPWpGaD
Capecitabine—Cough—Epirubicin—prostate cancer	2.01e-05	7.41e-05	CcSEcCtD
Capecitabine—Vision blurred—Doxorubicin—prostate cancer	2.01e-05	7.4e-05	CcSEcCtD
Capecitabine—Asthenia—Docetaxel—prostate cancer	2e-05	7.37e-05	CcSEcCtD
Capecitabine—Nausea—Etoposide—prostate cancer	1.99e-05	7.34e-05	CcSEcCtD
Capecitabine—Hypertension—Epirubicin—prostate cancer	1.99e-05	7.33e-05	CcSEcCtD
Capecitabine—TYMS—Integrated Pancreatic Cancer Pathway—AKT1—prostate cancer	1.98e-05	0.000161	CbGpPWpGaD
Capecitabine—Feeling abnormal—Prednisone—prostate cancer	1.98e-05	7.3e-05	CcSEcCtD
Capecitabine—Ill-defined disorder—Doxorubicin—prostate cancer	1.98e-05	7.29e-05	CcSEcCtD
Capecitabine—Pruritus—Docetaxel—prostate cancer	1.97e-05	7.26e-05	CcSEcCtD
Capecitabine—Anaemia—Doxorubicin—prostate cancer	1.97e-05	7.26e-05	CcSEcCtD
Capecitabine—Gastrointestinal pain—Prednisone—prostate cancer	1.96e-05	7.24e-05	CcSEcCtD
Capecitabine—TYMS—Metabolism—AKR1C3—prostate cancer	1.96e-05	0.00016	CbGpPWpGaD
Capecitabine—CDA—Metabolism—NOS3—prostate cancer	1.96e-05	0.00016	CbGpPWpGaD
Capecitabine—Chest pain—Epirubicin—prostate cancer	1.96e-05	7.22e-05	CcSEcCtD
Capecitabine—Arthralgia—Epirubicin—prostate cancer	1.96e-05	7.22e-05	CcSEcCtD
Capecitabine—Myalgia—Epirubicin—prostate cancer	1.96e-05	7.22e-05	CcSEcCtD
Capecitabine—Anxiety—Epirubicin—prostate cancer	1.95e-05	7.2e-05	CcSEcCtD
Capecitabine—TYMS—Metabolism—PRKACB—prostate cancer	1.95e-05	0.000159	CbGpPWpGaD
Capecitabine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—prostate cancer	1.95e-05	7.17e-05	CcSEcCtD
Capecitabine—Discomfort—Epirubicin—prostate cancer	1.94e-05	7.14e-05	CcSEcCtD
Capecitabine—TYMS—Metabolism—CYP17A1—prostate cancer	1.93e-05	0.000157	CbGpPWpGaD
Capecitabine—Malaise—Doxorubicin—prostate cancer	1.92e-05	7.08e-05	CcSEcCtD
Capecitabine—Dry mouth—Epirubicin—prostate cancer	1.92e-05	7.07e-05	CcSEcCtD
Capecitabine—Vertigo—Doxorubicin—prostate cancer	1.91e-05	7.05e-05	CcSEcCtD
Capecitabine—CYP2C9—Metabolism of lipids and lipoproteins—HSD3B1—prostate cancer	1.91e-05	0.000156	CbGpPWpGaD
Capecitabine—Syncope—Doxorubicin—prostate cancer	1.91e-05	7.04e-05	CcSEcCtD
Capecitabine—Urticaria—Prednisone—prostate cancer	1.91e-05	7.03e-05	CcSEcCtD
Capecitabine—Leukopenia—Doxorubicin—prostate cancer	1.91e-05	7.03e-05	CcSEcCtD
Capecitabine—Diarrhoea—Docetaxel—prostate cancer	1.91e-05	7.03e-05	CcSEcCtD
Capecitabine—Abdominal pain—Prednisone—prostate cancer	1.9e-05	7e-05	CcSEcCtD
Capecitabine—Body temperature increased—Prednisone—prostate cancer	1.9e-05	7e-05	CcSEcCtD
Capecitabine—Confusional state—Epirubicin—prostate cancer	1.89e-05	6.98e-05	CcSEcCtD
Capecitabine—TYMP—Metabolism—PIK3CG—prostate cancer	1.89e-05	0.000154	CbGpPWpGaD
Capecitabine—Palpitations—Doxorubicin—prostate cancer	1.88e-05	6.94e-05	CcSEcCtD
Capecitabine—Oedema—Epirubicin—prostate cancer	1.88e-05	6.93e-05	CcSEcCtD
Capecitabine—Loss of consciousness—Doxorubicin—prostate cancer	1.87e-05	6.9e-05	CcSEcCtD
Capecitabine—Infection—Epirubicin—prostate cancer	1.87e-05	6.88e-05	CcSEcCtD
Capecitabine—Cough—Doxorubicin—prostate cancer	1.86e-05	6.85e-05	CcSEcCtD
Capecitabine—Shock—Epirubicin—prostate cancer	1.85e-05	6.81e-05	CcSEcCtD
Capecitabine—Nervous system disorder—Epirubicin—prostate cancer	1.84e-05	6.79e-05	CcSEcCtD
Capecitabine—Dizziness—Docetaxel—prostate cancer	1.84e-05	6.79e-05	CcSEcCtD
Capecitabine—TYMS—Metabolism—NCOA2—prostate cancer	1.84e-05	0.00015	CbGpPWpGaD
Capecitabine—Thrombocytopenia—Epirubicin—prostate cancer	1.84e-05	6.78e-05	CcSEcCtD
Capecitabine—Hypertension—Doxorubicin—prostate cancer	1.84e-05	6.78e-05	CcSEcCtD
Capecitabine—Tachycardia—Epirubicin—prostate cancer	1.83e-05	6.76e-05	CcSEcCtD
Capecitabine—CYP2C9—Metabolism of lipids and lipoproteins—TBXAS1—prostate cancer	1.83e-05	0.000149	CbGpPWpGaD
Capecitabine—Skin disorder—Epirubicin—prostate cancer	1.83e-05	6.73e-05	CcSEcCtD
Capecitabine—Hyperhidrosis—Epirubicin—prostate cancer	1.82e-05	6.7e-05	CcSEcCtD
Capecitabine—Myalgia—Doxorubicin—prostate cancer	1.81e-05	6.68e-05	CcSEcCtD
Capecitabine—Arthralgia—Doxorubicin—prostate cancer	1.81e-05	6.68e-05	CcSEcCtD
Capecitabine—Chest pain—Doxorubicin—prostate cancer	1.81e-05	6.68e-05	CcSEcCtD
Capecitabine—CDA—Metabolism—PIK3CB—prostate cancer	1.81e-05	0.000147	CbGpPWpGaD
Capecitabine—TYMS—Cell Cycle, Mitotic—CDKN1B—prostate cancer	1.81e-05	0.000147	CbGpPWpGaD
Capecitabine—Anxiety—Doxorubicin—prostate cancer	1.81e-05	6.66e-05	CcSEcCtD
Capecitabine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—prostate cancer	1.8e-05	6.64e-05	CcSEcCtD
Capecitabine—CDA—Metabolism—PTGS2—prostate cancer	1.79e-05	0.000146	CbGpPWpGaD
Capecitabine—Discomfort—Doxorubicin—prostate cancer	1.79e-05	6.6e-05	CcSEcCtD
Capecitabine—Anorexia—Epirubicin—prostate cancer	1.79e-05	6.6e-05	CcSEcCtD
Capecitabine—TYMP—Metabolism—INS—prostate cancer	1.79e-05	0.000146	CbGpPWpGaD
Capecitabine—Dry mouth—Doxorubicin—prostate cancer	1.77e-05	6.54e-05	CcSEcCtD
Capecitabine—Vomiting—Docetaxel—prostate cancer	1.77e-05	6.53e-05	CcSEcCtD
Capecitabine—TYMS—Cell Cycle—MDM2—prostate cancer	1.77e-05	0.000144	CbGpPWpGaD
Capecitabine—Hypersensitivity—Prednisone—prostate cancer	1.77e-05	6.52e-05	CcSEcCtD
Capecitabine—CYP2C9—Metabolism of lipids and lipoproteins—ABCG5—prostate cancer	1.76e-05	0.000144	CbGpPWpGaD
Capecitabine—TYMS—Metabolism—SLC5A5—prostate cancer	1.76e-05	0.000143	CbGpPWpGaD
Capecitabine—Rash—Docetaxel—prostate cancer	1.76e-05	6.47e-05	CcSEcCtD
Capecitabine—Hypotension—Epirubicin—prostate cancer	1.76e-05	6.47e-05	CcSEcCtD
Capecitabine—Dermatitis—Docetaxel—prostate cancer	1.75e-05	6.47e-05	CcSEcCtD
Capecitabine—DPYD—Metabolism—PTEN—prostate cancer	1.75e-05	0.000143	CbGpPWpGaD
Capecitabine—Confusional state—Doxorubicin—prostate cancer	1.75e-05	6.46e-05	CcSEcCtD
Capecitabine—TYMP—Metabolism—CREBBP—prostate cancer	1.75e-05	0.000143	CbGpPWpGaD
Capecitabine—Headache—Docetaxel—prostate cancer	1.75e-05	6.43e-05	CcSEcCtD
Capecitabine—Oedema—Doxorubicin—prostate cancer	1.74e-05	6.41e-05	CcSEcCtD
Capecitabine—Infection—Doxorubicin—prostate cancer	1.73e-05	6.37e-05	CcSEcCtD
Capecitabine—TYMS—Cell Cycle, Mitotic—CCND1—prostate cancer	1.72e-05	0.00014	CbGpPWpGaD
Capecitabine—Asthenia—Prednisone—prostate cancer	1.72e-05	6.35e-05	CcSEcCtD
Capecitabine—TYMS—Metabolism—CYP2E1—prostate cancer	1.72e-05	0.00014	CbGpPWpGaD
Capecitabine—Musculoskeletal discomfort—Epirubicin—prostate cancer	1.71e-05	6.31e-05	CcSEcCtD
Capecitabine—Shock—Doxorubicin—prostate cancer	1.71e-05	6.3e-05	CcSEcCtD
Capecitabine—Nervous system disorder—Doxorubicin—prostate cancer	1.71e-05	6.28e-05	CcSEcCtD
Capecitabine—CYP2C9—Metabolism of lipids and lipoproteins—HSD3B2—prostate cancer	1.7e-05	0.000139	CbGpPWpGaD
Capecitabine—Thrombocytopenia—Doxorubicin—prostate cancer	1.7e-05	6.27e-05	CcSEcCtD
Capecitabine—Pruritus—Prednisone—prostate cancer	1.7e-05	6.27e-05	CcSEcCtD
Capecitabine—Insomnia—Epirubicin—prostate cancer	1.7e-05	6.26e-05	CcSEcCtD
Capecitabine—TYMS—Metabolism—NQO1—prostate cancer	1.7e-05	0.000138	CbGpPWpGaD
Capecitabine—Tachycardia—Doxorubicin—prostate cancer	1.7e-05	6.25e-05	CcSEcCtD
Capecitabine—Skin disorder—Doxorubicin—prostate cancer	1.69e-05	6.22e-05	CcSEcCtD
Capecitabine—Paraesthesia—Epirubicin—prostate cancer	1.69e-05	6.22e-05	CcSEcCtD
Capecitabine—Hyperhidrosis—Doxorubicin—prostate cancer	1.68e-05	6.2e-05	CcSEcCtD
Capecitabine—Dyspnoea—Epirubicin—prostate cancer	1.68e-05	6.17e-05	CcSEcCtD
Capecitabine—DPYD—Metabolism—EP300—prostate cancer	1.67e-05	0.000136	CbGpPWpGaD
Capecitabine—TYMS—Metabolism—TH—prostate cancer	1.67e-05	0.000136	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—GRHL1—prostate cancer	1.67e-05	0.000136	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—CSAD—prostate cancer	1.67e-05	0.000136	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—TST—prostate cancer	1.67e-05	0.000136	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—CBR1—prostate cancer	1.67e-05	0.000136	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—ADI1—prostate cancer	1.67e-05	0.000136	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—PSAT1—prostate cancer	1.67e-05	0.000136	CbGpPWpGaD
Capecitabine—TYMS—Cell Cycle, Mitotic—CDKN1A—prostate cancer	1.67e-05	0.000136	CbGpPWpGaD
Capecitabine—TYMP—Metabolism—PIK3CD—prostate cancer	1.66e-05	0.000135	CbGpPWpGaD
Capecitabine—Anorexia—Doxorubicin—prostate cancer	1.66e-05	6.11e-05	CcSEcCtD
Capecitabine—TYMS—Metabolism—CYP3A4—prostate cancer	1.65e-05	0.000135	CbGpPWpGaD
Capecitabine—Nausea—Docetaxel—prostate cancer	1.65e-05	6.1e-05	CcSEcCtD
Capecitabine—Dyspepsia—Epirubicin—prostate cancer	1.65e-05	6.1e-05	CcSEcCtD
Capecitabine—Diarrhoea—Prednisone—prostate cancer	1.64e-05	6.06e-05	CcSEcCtD
Capecitabine—CYP2C9—Metabolism of lipids and lipoproteins—LRP2—prostate cancer	1.63e-05	0.000133	CbGpPWpGaD
Capecitabine—Decreased appetite—Epirubicin—prostate cancer	1.63e-05	6.02e-05	CcSEcCtD
Capecitabine—TYMS—Metabolism—CYP1B1—prostate cancer	1.63e-05	0.000133	CbGpPWpGaD
Capecitabine—Hypotension—Doxorubicin—prostate cancer	1.62e-05	5.99e-05	CcSEcCtD
Capecitabine—Gastrointestinal disorder—Epirubicin—prostate cancer	1.62e-05	5.98e-05	CcSEcCtD
Capecitabine—Fatigue—Epirubicin—prostate cancer	1.62e-05	5.97e-05	CcSEcCtD
Capecitabine—TYMS—Cell Cycle—CDKN1B—prostate cancer	1.62e-05	0.000132	CbGpPWpGaD
Capecitabine—Constipation—Epirubicin—prostate cancer	1.61e-05	5.92e-05	CcSEcCtD
Capecitabine—Pain—Epirubicin—prostate cancer	1.61e-05	5.92e-05	CcSEcCtD
Capecitabine—CYP2C9—Metabolism of lipids and lipoproteins—P4HB—prostate cancer	1.6e-05	0.000131	CbGpPWpGaD
Capecitabine—Dizziness—Prednisone—prostate cancer	1.59e-05	5.86e-05	CcSEcCtD
Capecitabine—TYMS—Cell Cycle, Mitotic—EP300—prostate cancer	1.59e-05	0.000129	CbGpPWpGaD
Capecitabine—Musculoskeletal discomfort—Doxorubicin—prostate cancer	1.58e-05	5.84e-05	CcSEcCtD
Capecitabine—TYMS—Metabolism—GGT1—prostate cancer	1.58e-05	0.000128	CbGpPWpGaD
Capecitabine—Insomnia—Doxorubicin—prostate cancer	1.57e-05	5.8e-05	CcSEcCtD
Capecitabine—TYMP—Metabolism—NOS3—prostate cancer	1.57e-05	0.000128	CbGpPWpGaD
Capecitabine—CDA—Metabolism—PTEN—prostate cancer	1.56e-05	0.000127	CbGpPWpGaD
Capecitabine—Paraesthesia—Doxorubicin—prostate cancer	1.56e-05	5.75e-05	CcSEcCtD
Capecitabine—CYP2C9—Metabolism—UGT2B15—prostate cancer	1.55e-05	0.000127	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—GRHPR—prostate cancer	1.55e-05	0.000127	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—CKMT2—prostate cancer	1.55e-05	0.000127	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—UGT2B17—prostate cancer	1.55e-05	0.000127	CbGpPWpGaD
Capecitabine—TYMS—Metabolism—NCOA1—prostate cancer	1.55e-05	0.000126	CbGpPWpGaD
Capecitabine—Dyspnoea—Doxorubicin—prostate cancer	1.55e-05	5.71e-05	CcSEcCtD
Capecitabine—Feeling abnormal—Epirubicin—prostate cancer	1.55e-05	5.71e-05	CcSEcCtD
Capecitabine—TYMS—Cell Cycle—CCND1—prostate cancer	1.54e-05	0.000126	CbGpPWpGaD
Capecitabine—Gastrointestinal pain—Epirubicin—prostate cancer	1.54e-05	5.66e-05	CcSEcCtD
Capecitabine—Dyspepsia—Doxorubicin—prostate cancer	1.53e-05	5.64e-05	CcSEcCtD
Capecitabine—TYMS—Metabolism—CYP19A1—prostate cancer	1.53e-05	0.000125	CbGpPWpGaD
Capecitabine—Vomiting—Prednisone—prostate cancer	1.53e-05	5.63e-05	CcSEcCtD
Capecitabine—CYP2C9—Metabolism of lipids and lipoproteins—SULT2A1—prostate cancer	1.52e-05	0.000124	CbGpPWpGaD
Capecitabine—Rash—Prednisone—prostate cancer	1.51e-05	5.58e-05	CcSEcCtD
Capecitabine—Dermatitis—Prednisone—prostate cancer	1.51e-05	5.58e-05	CcSEcCtD
Capecitabine—Decreased appetite—Doxorubicin—prostate cancer	1.51e-05	5.57e-05	CcSEcCtD
Capecitabine—Headache—Prednisone—prostate cancer	1.51e-05	5.55e-05	CcSEcCtD
Capecitabine—Gastrointestinal disorder—Doxorubicin—prostate cancer	1.5e-05	5.53e-05	CcSEcCtD
Capecitabine—Fatigue—Doxorubicin—prostate cancer	1.5e-05	5.52e-05	CcSEcCtD
Capecitabine—CYP2C9—Metabolism of lipids and lipoproteins—MED12—prostate cancer	1.49e-05	0.000122	CbGpPWpGaD
Capecitabine—Urticaria—Epirubicin—prostate cancer	1.49e-05	5.5e-05	CcSEcCtD
Capecitabine—TYMS—Cell Cycle—CDKN1A—prostate cancer	1.49e-05	0.000122	CbGpPWpGaD
Capecitabine—CDA—Metabolism—EP300—prostate cancer	1.49e-05	0.000121	CbGpPWpGaD
Capecitabine—Pain—Doxorubicin—prostate cancer	1.49e-05	5.48e-05	CcSEcCtD
Capecitabine—Constipation—Doxorubicin—prostate cancer	1.49e-05	5.48e-05	CcSEcCtD
Capecitabine—Body temperature increased—Epirubicin—prostate cancer	1.49e-05	5.47e-05	CcSEcCtD
Capecitabine—Abdominal pain—Epirubicin—prostate cancer	1.49e-05	5.47e-05	CcSEcCtD
Capecitabine—TYMS—Metabolism—RXRA—prostate cancer	1.48e-05	0.00012	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—NAGLU—prostate cancer	1.46e-05	0.000119	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—SULT2B1—prostate cancer	1.46e-05	0.000119	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—AOX1—prostate cancer	1.46e-05	0.000119	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—MBTPS1—prostate cancer	1.46e-05	0.000119	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—RFK—prostate cancer	1.46e-05	0.000119	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—PGAM2—prostate cancer	1.46e-05	0.000119	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—GSTM3—prostate cancer	1.46e-05	0.000119	CbGpPWpGaD
Capecitabine—TYMP—Metabolism—PIK3CB—prostate cancer	1.45e-05	0.000118	CbGpPWpGaD
Capecitabine—TYMP—Metabolism—PTGS2—prostate cancer	1.43e-05	0.000117	CbGpPWpGaD
Capecitabine—Feeling abnormal—Doxorubicin—prostate cancer	1.43e-05	5.28e-05	CcSEcCtD
Capecitabine—CYP2C9—Metabolism of lipids and lipoproteins—NCOA3—prostate cancer	1.43e-05	0.000116	CbGpPWpGaD
Capecitabine—Nausea—Prednisone—prostate cancer	1.43e-05	5.26e-05	CcSEcCtD
Capecitabine—TYMS—Metabolism—COMT—prostate cancer	1.42e-05	0.000116	CbGpPWpGaD
Capecitabine—Gastrointestinal pain—Doxorubicin—prostate cancer	1.42e-05	5.24e-05	CcSEcCtD
Capecitabine—TYMS—Cell Cycle—EP300—prostate cancer	1.42e-05	0.000116	CbGpPWpGaD
Capecitabine—TYMS—Metabolism—GSTP1—prostate cancer	1.42e-05	0.000115	CbGpPWpGaD
Capecitabine—TYMS—Metabolism—ITPR1—prostate cancer	1.39e-05	0.000113	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—AMACR—prostate cancer	1.39e-05	0.000113	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—CYP3A43—prostate cancer	1.39e-05	0.000113	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—NAT1—prostate cancer	1.39e-05	0.000113	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—SRD5A2—prostate cancer	1.39e-05	0.000113	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—DEGS1—prostate cancer	1.39e-05	0.000113	CbGpPWpGaD
Capecitabine—Hypersensitivity—Epirubicin—prostate cancer	1.38e-05	5.1e-05	CcSEcCtD
Capecitabine—TYMS—Cell Cycle, Mitotic—MYC—prostate cancer	1.38e-05	0.000113	CbGpPWpGaD
Capecitabine—Urticaria—Doxorubicin—prostate cancer	1.38e-05	5.09e-05	CcSEcCtD
Capecitabine—Body temperature increased—Doxorubicin—prostate cancer	1.37e-05	5.07e-05	CcSEcCtD
Capecitabine—Abdominal pain—Doxorubicin—prostate cancer	1.37e-05	5.07e-05	CcSEcCtD
Capecitabine—CYP2C9—Metabolism of lipids and lipoproteins—HPGDS—prostate cancer	1.36e-05	0.000111	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism of lipids and lipoproteins—CYP2C19—prostate cancer	1.35e-05	0.00011	CbGpPWpGaD
Capecitabine—Asthenia—Epirubicin—prostate cancer	1.35e-05	4.97e-05	CcSEcCtD
Capecitabine—Pruritus—Epirubicin—prostate cancer	1.33e-05	4.9e-05	CcSEcCtD
Capecitabine—CYP2C9—Metabolism—HSD17B1—prostate cancer	1.32e-05	0.000108	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism of lipids and lipoproteins—ACHE—prostate cancer	1.32e-05	0.000108	CbGpPWpGaD
Capecitabine—TYMS—Metabolism—GSTM1—prostate cancer	1.3e-05	0.000106	CbGpPWpGaD
Capecitabine—Diarrhoea—Epirubicin—prostate cancer	1.29e-05	4.74e-05	CcSEcCtD
Capecitabine—Hypersensitivity—Doxorubicin—prostate cancer	1.28e-05	4.72e-05	CcSEcCtD
Capecitabine—TYMS—Metabolism—LPL—prostate cancer	1.28e-05	0.000104	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism of lipids and lipoproteins—AKR1C3—prostate cancer	1.27e-05	0.000104	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism of lipids and lipoproteins—PRKACB—prostate cancer	1.26e-05	0.000103	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism of lipids and lipoproteins—CYP17A1—prostate cancer	1.25e-05	0.000102	CbGpPWpGaD
Capecitabine—TYMP—Metabolism—PTEN—prostate cancer	1.25e-05	0.000102	CbGpPWpGaD
Capecitabine—Asthenia—Doxorubicin—prostate cancer	1.25e-05	4.6e-05	CcSEcCtD
Capecitabine—Dizziness—Epirubicin—prostate cancer	1.24e-05	4.58e-05	CcSEcCtD
Capecitabine—DPYD—Metabolism—PIK3CA—prostate cancer	1.24e-05	0.000101	CbGpPWpGaD
Capecitabine—TYMS—Cell Cycle—MYC—prostate cancer	1.24e-05	0.000101	CbGpPWpGaD
Capecitabine—TYMS—Metabolism—CYP1A1—prostate cancer	1.23e-05	0.0001	CbGpPWpGaD
Capecitabine—Pruritus—Doxorubicin—prostate cancer	1.23e-05	4.53e-05	CcSEcCtD
Capecitabine—TYMS—Metabolism—ERCC2—prostate cancer	1.22e-05	9.96e-05	CbGpPWpGaD
Capecitabine—Vomiting—Epirubicin—prostate cancer	1.19e-05	4.4e-05	CcSEcCtD
Capecitabine—TYMP—Metabolism—EP300—prostate cancer	1.19e-05	9.71e-05	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism of lipids and lipoproteins—NCOA2—prostate cancer	1.19e-05	9.71e-05	CbGpPWpGaD
Capecitabine—Diarrhoea—Doxorubicin—prostate cancer	1.19e-05	4.38e-05	CcSEcCtD
Capecitabine—Rash—Epirubicin—prostate cancer	1.18e-05	4.37e-05	CcSEcCtD
Capecitabine—Dermatitis—Epirubicin—prostate cancer	1.18e-05	4.36e-05	CcSEcCtD
Capecitabine—CYP2C9—Metabolism—HPGD—prostate cancer	1.18e-05	9.6e-05	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—B4GALT4—prostate cancer	1.18e-05	9.6e-05	CbGpPWpGaD
Capecitabine—Headache—Epirubicin—prostate cancer	1.18e-05	4.34e-05	CcSEcCtD
Capecitabine—Dizziness—Doxorubicin—prostate cancer	1.15e-05	4.24e-05	CcSEcCtD
Capecitabine—TYMS—Metabolism—MTHFR—prostate cancer	1.15e-05	9.36e-05	CbGpPWpGaD
Capecitabine—TYMS—Metabolism—PPARA—prostate cancer	1.13e-05	9.19e-05	CbGpPWpGaD
Capecitabine—Nausea—Epirubicin—prostate cancer	1.12e-05	4.11e-05	CcSEcCtD
Capecitabine—CYP2C9—Metabolism—TNFRSF21—prostate cancer	1.11e-05	9.02e-05	CbGpPWpGaD
Capecitabine—Vomiting—Doxorubicin—prostate cancer	1.11e-05	4.07e-05	CcSEcCtD
Capecitabine—CDA—Metabolism—PIK3CA—prostate cancer	1.1e-05	8.99e-05	CbGpPWpGaD
Capecitabine—Rash—Doxorubicin—prostate cancer	1.1e-05	4.04e-05	CcSEcCtD
Capecitabine—Dermatitis—Doxorubicin—prostate cancer	1.1e-05	4.04e-05	CcSEcCtD
Capecitabine—Headache—Doxorubicin—prostate cancer	1.09e-05	4.01e-05	CcSEcCtD
Capecitabine—CYP2C9—Metabolism—MTAP—prostate cancer	1.08e-05	8.78e-05	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—CYP7B1—prostate cancer	1.08e-05	8.78e-05	CbGpPWpGaD
Capecitabine—TYMS—Metabolism—CAV1—prostate cancer	1.06e-05	8.64e-05	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism of lipids and lipoproteins—CYP1B1—prostate cancer	1.05e-05	8.58e-05	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—SULT1E1—prostate cancer	1.05e-05	8.55e-05	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—SRD5A1—prostate cancer	1.05e-05	8.55e-05	CbGpPWpGaD
Capecitabine—Nausea—Doxorubicin—prostate cancer	1.03e-05	3.81e-05	CcSEcCtD
Capecitabine—CYP2C9—Metabolism of lipids and lipoproteins—GGT1—prostate cancer	1.02e-05	8.31e-05	CbGpPWpGaD
Capecitabine—TYMS—Cell Cycle—TP53—prostate cancer	1.02e-05	8.28e-05	CbGpPWpGaD
Capecitabine—DPYD—Metabolism—AKT1—prostate cancer	1.01e-05	8.24e-05	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism of lipids and lipoproteins—NCOA1—prostate cancer	1e-05	8.18e-05	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—ACSL4—prostate cancer	1e-05	8.16e-05	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—HSD17B3—prostate cancer	1e-05	8.16e-05	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism of lipids and lipoproteins—CYP19A1—prostate cancer	9.9e-06	8.07e-05	CbGpPWpGaD
Capecitabine—TYMS—Metabolism—PIK3CG—prostate cancer	9.66e-06	7.87e-05	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—PHGDH—prostate cancer	9.6e-06	7.82e-05	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—ARG2—prostate cancer	9.6e-06	7.82e-05	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—UMPS—prostate cancer	9.6e-06	7.82e-05	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism of lipids and lipoproteins—RXRA—prostate cancer	9.55e-06	7.78e-05	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—LDHB—prostate cancer	9.42e-06	7.67e-05	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—CYP3A5—prostate cancer	9.24e-06	7.53e-05	CbGpPWpGaD
Capecitabine—TYMS—Metabolism—INS—prostate cancer	9.14e-06	7.45e-05	CbGpPWpGaD
Capecitabine—CDA—Metabolism—AKT1—prostate cancer	9.01e-06	7.34e-05	CbGpPWpGaD
Capecitabine—TYMS—Metabolism—CREBBP—prostate cancer	8.95e-06	7.29e-05	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—PDHA1—prostate cancer	8.93e-06	7.27e-05	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—TCN2—prostate cancer	8.93e-06	7.27e-05	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—UCP3—prostate cancer	8.93e-06	7.27e-05	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—GSTA3—prostate cancer	8.93e-06	7.27e-05	CbGpPWpGaD
Capecitabine—TYMP—Metabolism—PIK3CA—prostate cancer	8.82e-06	7.18e-05	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—SLC22A3—prostate cancer	8.52e-06	6.94e-05	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—HSD3B1—prostate cancer	8.52e-06	6.94e-05	CbGpPWpGaD
Capecitabine—TYMS—Metabolism—PIK3CD—prostate cancer	8.49e-06	6.92e-05	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism of lipids and lipoproteins—LPL—prostate cancer	8.26e-06	6.73e-05	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—GSTA4—prostate cancer	8.16e-06	6.65e-05	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—TBXAS1—prostate cancer	8.16e-06	6.65e-05	CbGpPWpGaD
Capecitabine—TYMS—Metabolism—NOS3—prostate cancer	8.02e-06	6.53e-05	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A1—prostate cancer	7.98e-06	6.5e-05	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—GSTA2—prostate cancer	7.96e-06	6.48e-05	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—ABCG5—prostate cancer	7.86e-06	6.4e-05	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—SULT1A1—prostate cancer	7.86e-06	6.4e-05	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—GSTA1—prostate cancer	7.68e-06	6.25e-05	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—NAT2—prostate cancer	7.59e-06	6.18e-05	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—GSTO1—prostate cancer	7.59e-06	6.18e-05	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—HSD3B2—prostate cancer	7.59e-06	6.18e-05	CbGpPWpGaD
Capecitabine—TYMS—Metabolism—PIK3CB—prostate cancer	7.4e-06	6.03e-05	CbGpPWpGaD
Capecitabine—TYMS—Metabolism—PTGS2—prostate cancer	7.33e-06	5.97e-05	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism of lipids and lipoproteins—PPARA—prostate cancer	7.3e-06	5.95e-05	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—PLCB2—prostate cancer	7.28e-06	5.93e-05	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—LRP2—prostate cancer	7.28e-06	5.93e-05	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—CYP2C18—prostate cancer	7.28e-06	5.93e-05	CbGpPWpGaD
Capecitabine—TYMP—Metabolism—AKT1—prostate cancer	7.2e-06	5.87e-05	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—P4HB—prostate cancer	7.14e-06	5.81e-05	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—SLC22A1—prostate cancer	6.94e-06	5.66e-05	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism of lipids and lipoproteins—CAV1—prostate cancer	6.86e-06	5.59e-05	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—SULT2A1—prostate cancer	6.77e-06	5.51e-05	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—MED12—prostate cancer	6.66e-06	5.42e-05	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—GNG5—prostate cancer	6.6e-06	5.38e-05	CbGpPWpGaD
Capecitabine—TYMS—Metabolism—PTEN—prostate cancer	6.39e-06	5.21e-05	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—NCOA3—prostate cancer	6.36e-06	5.18e-05	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—prostate cancer	6.25e-06	5.09e-05	CbGpPWpGaD
Capecitabine—TYMS—Metabolism—EP300—prostate cancer	6.1e-06	4.97e-05	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—HPGDS—prostate cancer	6.07e-06	4.94e-05	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—CYP2C19—prostate cancer	6.03e-06	4.91e-05	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—ACHE—prostate cancer	5.89e-06	4.79e-05	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—GSTT1—prostate cancer	5.89e-06	4.79e-05	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—CYP2A6—prostate cancer	5.82e-06	4.74e-05	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—prostate cancer	5.8e-06	4.72e-05	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—AKR1C3—prostate cancer	5.66e-06	4.61e-05	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—PRKACB—prostate cancer	5.63e-06	4.59e-05	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—CYP17A1—prostate cancer	5.57e-06	4.54e-05	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—prostate cancer	5.5e-06	4.48e-05	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—NCOA2—prostate cancer	5.31e-06	4.32e-05	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—SLC5A5—prostate cancer	5.06e-06	4.13e-05	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—CYP2E1—prostate cancer	4.95e-06	4.03e-05	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—NQO1—prostate cancer	4.89e-06	3.98e-05	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—TH—prostate cancer	4.82e-06	3.93e-05	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—prostate cancer	4.79e-06	3.9e-05	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—CYP3A4—prostate cancer	4.77e-06	3.89e-05	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—prostate cancer	4.75e-06	3.87e-05	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—CYP1B1—prostate cancer	4.69e-06	3.82e-05	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—GGT1—prostate cancer	4.54e-06	3.7e-05	CbGpPWpGaD
Capecitabine—TYMS—Metabolism—PIK3CA—prostate cancer	4.51e-06	3.67e-05	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—NCOA1—prostate cancer	4.47e-06	3.64e-05	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—CYP19A1—prostate cancer	4.41e-06	3.59e-05	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—RXRA—prostate cancer	4.26e-06	3.47e-05	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	4.14e-06	3.37e-05	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—COMT—prostate cancer	4.1e-06	3.34e-05	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—GSTP1—prostate cancer	4.08e-06	3.32e-05	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—ITPR1—prostate cancer	4.01e-06	3.27e-05	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism of lipids and lipoproteins—EP300—prostate cancer	3.95e-06	3.22e-05	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—TYMS—prostate cancer	3.79e-06	3.09e-05	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—GSTM1—prostate cancer	3.75e-06	3.05e-05	CbGpPWpGaD
Capecitabine—TYMS—Metabolism—AKT1—prostate cancer	3.69e-06	3e-05	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—LPL—prostate cancer	3.68e-06	3e-05	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—CYP1A1—prostate cancer	3.55e-06	2.9e-05	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—ERCC2—prostate cancer	3.52e-06	2.87e-05	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—MTHFR—prostate cancer	3.31e-06	2.7e-05	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—PPARA—prostate cancer	3.25e-06	2.65e-05	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—CAV1—prostate cancer	3.06e-06	2.49e-05	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	2.92e-06	2.38e-05	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—PIK3CG—prostate cancer	2.78e-06	2.27e-05	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—INS—prostate cancer	2.64e-06	2.15e-05	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—CREBBP—prostate cancer	2.58e-06	2.1e-05	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—PIK3CD—prostate cancer	2.45e-06	1.99e-05	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—NOS3—prostate cancer	2.31e-06	1.88e-05	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—PIK3CB—prostate cancer	2.13e-06	1.74e-05	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—PTGS2—prostate cancer	2.11e-06	1.72e-05	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—PTEN—prostate cancer	1.84e-06	1.5e-05	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—EP300—prostate cancer	1.76e-06	1.43e-05	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—PIK3CA—prostate cancer	1.3e-06	1.06e-05	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—AKT1—prostate cancer	1.06e-06	8.65e-06	CbGpPWpGaD
